Robert W. Baird Trims Danaher (NYSE:DHR) Target Price to $277.00

Danaher (NYSE:DHR) had its target price trimmed by Robert W. Baird from $278.00 to $277.00 in a report published on Wednesday morning, Benzinga reports. The brokerage currently has an outperform rating on the conglomerate’s stock.

Several other equities analysts also recently commented on DHR. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Barclays increased their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI boosted their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Stock Down 1.0 %

Danaher stock opened at $245.41 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The company’s 50-day moving average is $270.00 and its 200-day moving average is $260.34. The firm has a market capitalization of $181.77 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. The business’s revenue was up 3.1% compared to the same quarter last year. Sell-side analysts anticipate that Danaher will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,059 shares of company stock valued at $8,400,897. 11.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Tsfg LLC grew its position in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the second quarter valued at about $25,000. nVerses Capital LLC bought a new stake in shares of Danaher during the second quarter worth about $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher in the first quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new position in Danaher in the 2nd quarter valued at approximately $51,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.